Citations

Clear

171 citation(s) found for "Moss, M".

Liver transplantation: embracing the future with machine perfusion
Wiederkehr, Henrique de Aguiar , Nguyen, Michelle , Moss, Adyr A. , Mathur, Amit K. , Nunez-Nateras, Rafael, Wiederkehr, Júlio César , Coelho, Júlio Cézar Uili , Nguyen, Michelle C , Moss, Adyr , Mathur, Amit , Núñez-Nateras, Rafael

Mayo Clinic

ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo) | July 27, 2026 | Volume: 39 | Issue: No issue available | Pages: No page available

10.1590/0102-672020260000017e1946 | PMID 42585392 Get It

ABSTRACT Despite the annual increase in liver transplants, a persistent disparity between suitable donors and recipients continues to challenge the transplant community. The introduction of machine perfusion emerged as a novel approach to organ preservation. This technique, which utilizes extended criteria donor grafts, is expected to reduce rejection rates and expand the donor pool. Its principle, like that of any ex vivo machine perfusion, is based on the continuous supply of nutrients and oxygen to maintain cellular metabolism while interrupting anaerobic processes. This helps prevent conditions such as ischemia-reperfusion injury, early graft dysfunction, and ischemic cholangiopathy, which can lead to graft loss and the need for retransplantation. There are two main modes of ex vivo machine perfusion: hypothermic and normothermic, differentiated by the operating temperature. Utilizing ex situ perfusion machines presents a promising opportunity to increase liver graft usage and reduce waitlist times. However, it is crucial to evaluate how much this technology would raise the overall cost of transplants. In Brazil, implementing a machine perfusion program may encounter unique challenges not seen in other countries. These challenges include limited access to the healthcare system for high-risk liver transplant candidates, long waiting lists, inadequate support for organ donors, reliance solely on deceased brain-dead donors, since donation after cardiac death is not ethically accepted, and geographical barriers.
E-034 Geographic disparities in functional recovery after successful thrombectomy in the United States
Hijazi, D, Chacon, A, Chalhoub, R, Tfaily, A, Spiotta, A, Rai, A, Wolfe, S, Jabbour, P, Ogilvy, C, Ezzeldin, M, Mascitelli, J, Siddiqui, F, Howard, B, Cawley, M, Altschul, D, Park, M, Levitt, M, Brinjikji, W, Moss, M, Dye, J, Limaye, K, Alaraj, A, Kan, P, Polifka, A, Grandhi, R, Mokin, M, Starke, R, Guess, S, Surbhi, S, Goyal, N, Grossberg, J, Alawieh, A, Chalhoub, Reda, Spiotta, A, Rai, A , Jabbour, Pascal , Ogilvy, C, Ezzeldin, Mohamad , Mascitelli, J, Siddiqui, Fazeel , Howard, Brian M., Moss, M, Dye, Justin , Limaye, K, Alaraj, Ali , Polifka, A, Grandhi, R, Starke, R, Surbhi, Satya , Grossberg, J

Mayo Clinic

SNIS 23rd Annual Meeting Electronic Poster Abstracts | July 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: A109.2-A110

10.1136/jnis-2026-snis.138 Get It

Minor stroke, major stakes: impact of procedure duration on thrombectomy outcomes in minor stroke
Kasem, Rahim Abo, Baba, Bachar El, Ma, Tianwen, Zelmanovich, Rebecca, Pabaney, Aqueel, Khelo, Roy Raheb, Giraudo, Francesca, Chandler, Katherine, Elawady, Sameh Samir, Chalhoub, Reda, Levitt, Michael R., Mascitelli, Justin, Cawley, Charles Michael, Akbik, Feras, Chisango, Zvipo, Wolfe, Stacey Quintero, Kim, Joon-Tae, Jabbour, Pascal, Yoshimura, Shinichi, Maier, Ilko, Ogilvy, Christopher S., Ezzeldin, Mohamad, Psychogios, Marios-Nikos, Siddiqui, Fazeel, Navia, Pedro, Goyal, Nitin, Arthur, Adam S., Romano, Daniele G., Fragata, Isabel, Daglioglu, Ergun, Altschul, David, Park, Min S., Crosa, Roberto, Brinjikji, Waleed, Moss, Mark, Dye, Justin, Alaraj, Ali, Kan, Peter, Limaye, Kaustubh, Mokin, Maxim, Starke, Robert M., Spiotta, Alejandro M., Grossberg, Jonathan A , Alawieh, Ali M., Kasem, Rahim Abo , Baba, Bachar El , Ma, Tianwen , Zelmanovich, Rebecca , Pabaney, Aqueel, Khelo, Roy Raheb , Giraudo, Francesca, Chacón-Aponte, Ariana Alejandra , Chandler, Katherine , Elawady, Sameh Samir , Howard, Brian M , Levitt, Michael R. , Grandhi, Ramesh , Mascitelli, Justin R , Cawley, Charles Michael, Akbik, Feras , Chisango, Zvipo Mutsa , Wolfe, Stacey Q , Kim, Joon‐Tae , Jabbour, Pascal , Maier, Ilko , Ogilvy, Christopher S. , Ezzeldin, Mohamad , Psychogios, Marios‐Nikos , Navía, Pedro , Goyal, Nitin , Arthur, Adam S., Romano, Daniele Giuseppe , Fragata, Isabel , Dağlıoğlu, Ergün , Altschul, David , Crosa, Roberto , Brinjikji, Waleed , Moss, Mark, Dye, Justin , Alaraj, Ali , Limaye, Kaustubh , Mokin, Maxim , Starke, Robert M. , Spiotta, Alejandro M , Alawieh, Ali

Mayo Clinic

Journal of Neurosurgery | July 15, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-12

10.3171/2026.2.jns252558 | PMID 42468039 Get It

OBJECTIVE Endovascular thrombectomy (EVT) for acute large-vessel occlusion stroke is well established, yet its role in patients presenting with minor stroke symptoms (National Institutes of Health Stroke Scale [NIHSS] score < 6) remains unclear. Prior studies have not accounted for intraprocedural factors that may influence outcomes in this subgroup. METHODS The authors analyzed 5693 patients from the STAR (Stroke and Thrombectomy and Aneurysm Registry), including 398 with low NIHSS scores, to evaluate the association between procedure time (PT) and outcomes. Among patients with low NIHSS scores, propensity score matching was used to compare outcomes between those with PT ≤ 35 versus > 35 minutes, a cutoff defined using receiver operating characteristic curve analysis. The authors performed a meta-analysis of studies reporting best medical management (BMM) outcomes in patients with low NIHSS scores. To compare these with EVT-treated patients, a matched BMM comparator cohort using stratification on pooled baseline characteristics was constructed. Outcomes included 90-day functional independence (modified Rankin Scale [mRS] scores 0–2), intracranial hemorrhage, and mortality. RESULTS PT had a stronger negative effect on outcomes in patients with low NIHSS scores compared with those with high scores, with a steeper decline in functional independence per minute of PT (slope: –0.45% vs –0.21%; p = 0.03 for interaction). Among patients with low scores, PT ≤ 35 minutes was associated with higher 90-day functional independence compared with the propensity score–matching cohort with PT > 35 minutes (82.6% vs 59.0%, p < 0.001). When benchmarked against BMM (75.2% mRS scores 0–2), patients undergoing EVT within 35 minutes had superior outcomes (85.1%, p = 0.047). In contrast, EVT with PT > 35 minutes resulted in worse outcomes than BMM (mRS scores 0–2: 59.8%, p = 0.008). The number needed to treat for PT ≤ 35 minutes was 10, whereas PT > 35 minutes yielded a number needed to harm of 6. CONCLUSIONS PT critically modulates the benefit of EVT in minor stroke. While efficient EVT yields better outcomes than BMM, prolonged procedures are associated with harm. These findings may explain prior inconsistent evidence on EVT in patients with low NIHSS scores and underscore the need to individualize procedural thresholds in this population.
C66-08 Pulmonary Hypertension in ILD Transplant Candidates: Functional Burden and Utility of Screening Tools
Bajwa, A, Gutierrez-Gallegos, P, Karki, D, Saunders, H, Narula, T, Moss, J E, Deleveaux, S, Delgado, J, Gore, S S, Burger, C D, Gore, Shivanjali , Gutierrez‐Gallegos, Paola , Saunders, Hollie , Narula, T., Moss, John E. , Burger, C D

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.5854 Get It

Abstract Rationale Pulmonary hypertension (PH) develops in up to 50% of patients with advanced interstitial lung disease (ILD) and is associated with increased morbidity, mortality, and impaired quality of life. Early recognition is essential, as available therapy for ILD-PH has been shown to improve outcomes. Identifying physiologic markers of PH may facilitate earlier referral for right heart catheterization (RHC) and initiation of targeted treatment. Thus, this study aimed to (1) compare functional parameters between ILD patients with and without RHC-confirmed PH, and (2) assess the applicability of previously proposed ILD-PH screening criteria. Methods We retrospectively analyzed ILD transplant candidates with available pre-transplant pulmonary function tests (FVC%, DLCO%), echocardiographic right-ventricular systolic pressure (RVSP), six-minute walk distance (6MWD) with oxygen requirement, and RHC data. PH was defined according to the 2022 ESC/ERS criteria. Functional parameters were compared between patients with and without PH. Among those without a prior PH diagnosis, screening thresholds derived from previously published tools were applied (RVSP ≥ 35 mmHg, DLCO &lt; 40%, FVC/DLCO &gt; 1.6, 6MWD &lt; 350 m, or oxygen use during 6MWD). Results Of 107 ILD patients evaluated, 90 had complete RHC data (48 ILD-PH, 42 ILD without PH). Group comparisons are summarized in Table 1. Patients with PH had lower DLCO% (median 18.5 [11.5-26.7] vs 26.5 [20.0-34.7], p = 0.08), higher FVC/DLCO ratios (2.68 [2.1-3.4] vs 1.7 [1.4-2.6], p = 0.08), and higher RVSP (55 [39.7-63.2] vs 39.5 [29-48] mmHg, p = 0.002). Oxygen requirement during 6MWD was more frequent in ILD-PH (79.2% vs 61.9%, p = 0.08). Among patients with PH, 38 (79.16%) had no formal diagnosis prior to pre-transplant RHC. Of these cases, all (100%) met ≥3 screening criteria, most commonly DLCO &lt; 40% (n = 38, 100%), FVC/DLCO &gt; 1.6 (n = 37, 97.3%), and 6MWD &lt; 350 m (n = 33, 86.8%). Additionally, 32 patients (84.21%) met ≥4 criteria and 8 (21.05%) met all five criteria. Conclusion In ILD transplant candidates, patients with PH had worse functional profiles when compared to those without PH, and nearly 80% of PH cases were previously undiagnosed. Systematic application of validated PH screening tools in ILD populations may facilitate earlier recognition, potentially improving patient outcomes. This abstract is funded by: None
C63-05 Dupixent as a Treatment for Type 1 Hypersensitivity Reactions to Subcutaneous Treprostinil
Farrell, C, Olitsky, S, Moss, J E, Hountras, P, Moss, John E. , Hountras, Peter

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.5781 Get It

Abstract Introduction Pulmonary arterial hypertension (PAH) is a progressive and deadly disease characterized by pulmonary vascular remodeling and eventual right heart failure. A mainstay of treatment for PAH is prostacyclin therapy which can be delivered via continuous subcutaneous (SQ) or intravenous (IV) infusion. Infusion site reactions are a common occurrence with SQ Treprostinil resulting in discontinuation in approximately 10% of patients. Given that switching from SQ to IV prostacyclin therapy contains risks associated with long-term central venous access such as blood stream infections and deep venous thrombosis, the development of better strategies to improve SQ Treprostinil tolerability are needed. Case Report We report two patients with PAH who developed delayed infusion site reactions to SQ Treprostinil. Both patients were female, in their 30s, with severe group 1 PAH (mean pulmonary artery pressures of 44 and 81 mmHg on right heat catheterization at diagnosis), who had been on SQ Treprostinil for approximately 6 years on a dose around 60 ng/kg/min. Within two weeks of starting a new SQ infusion site, each patient developed a raised, hyperemic site reaction in the area of the infusion catheter draining yellow fluid (Figure 1). Skin patch testing was done from an ampule of preservative-free Treprostinil demonstrating a type 1 hypersensitivity reaction. There was no skin reaction to the Tegaderm dressing alone. Dupilumab 300 mg weekly SQ injections were started for these type 1 hypersensitivity reactions with resolution of the site reactions and pain. Because of this, both patients were able to remain on their SQ Treprostinil infusions. Discussion Infusion site reactions to SQ Treprostinil are common and can necessitate discontinuation of the medication. SQ Treprostinil infusion site reactions typically occur within 48 hours of establishing a new SQ infusion site and are thought to be a local vasodilatory reaction to the Treprostinil itself. These reactions can be minimized by analgesic pain medication and by increasing the Treprostinil infusion concentration. Here we describe two infusion site reactions that occurred two weeks after establishing a new site and were consistent with a type 1 hypersensitivity reaction. These reactions were successfully treated with Dupilumab which allowed the patients to remain on SQ Treprostinil. This abstract is funded by: None
Difficulties in Honoring Patient Requests for Hospice when Relying on Surrogate Decision-Makers: A Case Study
Meyer, Leigh, White, Lexi C., Moss, Mateo, Villanueva, Mark, Ingall, Timothy J., Guthrie, R , Murphy, Tyler, Trost, Lisa , Frase, Beverly, Collura, Christopher A., Meltzer, Ellen C. , Villanueva, Mark N, Meyer, Leigh , Guthrie, Richard V, Trost, Lisa, Collura, Christopher A.

Mayo Clinic

Journal of Law, Medicine & Ethics | May 15, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-4

10.1017/jme.2026.10251 | PMID 42138039 Get It

Abstract Honoring a patient’s wishes for end-of-life care can be challenging if the patient loses decision-making capacity and the identified alternate decision-maker will not respect the patient’s wishes. This article discusses how to proceed ethically and legally when the alternate decision-maker and care team disagree about respecting a patient’s end-of-life preferences.
ABSTRACT NUMBER: ESOC2026A269 DENTAL CARIES INDEPENDENTLY ASSOCIATED WITH INCREASED INCIDENT DEMENTIA RISK FROM THE ARIC STUDY
Barton, Alana, Sen, Souvik, Moss, Kevin, Selph, James, Demmer, Ryan, Lutsey, Pamela, Palta, Priya, Pikel, Karly, Rosamond, Wayne, Moss, Kevin, Demmer, Ryan T. , Lutsey, Pamela L. , Lakshminarayan, Kamakshi , Rosamond, wayne

Mayo Clinic

European Stroke Journal | May 6, 2026 | Volume: 11 | Issue: Supplement_1 | Pages: i139-i139

10.1093/esj/aakag023.232 Get It

Abstract Background and aims Dementia represents a growing global health burden, with vascular dementia and Alzheimer's disease accounting for most cases through cumulative cerebrovascular damage. While periodontal disease (PD) is associated with cognitive decline, dental caries represents a distinct oral infection pathway characterized by bacterial invasion and infection, potentially contributing to vascular brain injury through microbial translocation, endothelial dysfunction, systemic inflammation, and cerebral microvascular damage. The relationship between dental caries and incident dementia within a vascular framework remains understudied. Methods We analyzed 6,542 participants from the Atherosclerosis Risk in Communities (ARIC) Study who received dental examinations at Visit 4 (1996–1998) and followed for incident dementia through 2023 using standardized surveillance (Figure-1). Cox proportional hazards models with competing risk accounted for death. Multivariable models adjusted for demographic factors, cardiovascular risk factors, BMI, physical activity, education, income, insurance status, APOE4 genotype, PD, and regular dental care. Results Mean age was 62.4 years; 54% female, 82% White, and 18% Black. Dental caries was present in 20%. Over median 25-year follow-up, individuals with dental caries demonstrated significantly higher cumulative dementia incidence (Gray’s test p&lt;0.0001). After full adjustment, dental caries remained independently associated with increased dementia risk (adjusted HR 1.20, 95% CI 1.02–1.42), independent of PD and APOE4 status (Figure-2). Conclusions Dental caries was independently associated with increased incident dementia risk. These findings support a potential role for caries-related oral infection in vascular brain injury pathways relevant to vascular dementia and stroke-related cognitive impairment. Oral infection prevention may represent a modifiable target within cerebrovascular disease prevention strategies. Conflict of interest Alana E. Barton, Souvik Sen, Kevin Moss, James Selph, Ryan Demmer, Pamela L. Lutsey, Priya Palta, Kamakshi Lakshminarayan, Karly Pikel, Wayne Rosamond: nothing to disclose Figure 1 - belongs to Conclusions Figure 2 - belongs to Conclusions
ABSTRACT NUMBER: ESOC2026A271 INTERLEUKIN-6 LEVELS AND RISK OF INCIDENT DEMENTIA: THE ARIC STUDY
Pikel, Karly, Carmichael, Natasha, Barton, Alana, Moss, Kevin, Downey, Christine, Demmer, Ryan, Lutsey, Pamela, Sen, Souvik, Carmichael, Natasha S. , Moss, Kevin, Demmer, Ryan T. , Lutsey, Pamela L.

Mayo Clinic

European Stroke Journal | May 6, 2026 | Volume: 11 | Issue: Supplement_1 | Pages: i140-i140

10.1093/esj/aakag023.233 Get It

Abstract Background and aims Systemic inflammation has been implicated in cognitive decline and dementia pathogenesis. Interleukin-6 (IL-6), a pro-inflammatory cytokine associated with cardiovascular disease, may play a role in cerebrovascular and neurodegenerative processes. We examined the relationship between IL-6 levels and incident dementia risk using the Atherosclerosis Risk In Communities (ARIC) study. Methods ARIC study participants at Visit 4 (1996-1998) had IL-6 measurements and were followed for incident dementia over 25 years. IL-6 levels were dichotomized at the median value of 1.5 pg/mL. Incident dementia cases were identified through standardized surveillance. Cox proportional hazards regression calculated hazard ratios (HR) with 95% confidence intervals (CI), adjusting for age, race, gender, hypertension, diabetes, obesity, physical activity, smoking, alcohol use, education, income, insurance status, and ApoE-ε4 allele status. Results Participants (n=5,662; mean age 62.4±5.6 years, 55% female, 83% White, 17% Black) were followed for a median of 25 years. Those with IL-6 &gt;1.5 pg/mL demonstrated significantly increased dementia risk versus IL-6 ≤1.5 pg/mL. The crude HR was 1.23 (95% CI 1.11-1.37). After adjustment, the association remained significant with HR 1.13 (95% CI 1.01-1.27). Kaplan-Meier survival curves showed progressive divergence between groups, with lower dementia-free survival in the higher IL-6 group, log-rank p&lt;0.001. Conclusions Elevated mid-life IL-6 levels (&gt;1.5 pg/mL) independently predict increased long-term dementia risk over 25 years, even after adjusting for cardiovascular and sociodemographic confounders. These findings support systemic inflammation's role in dementia pathogenesis and highlight IL-6 as a potential biomarker for dementia risk. Conflict of interest Karly Pikel, Natasha Carmichael, Alana E. Barton, Kevin Moss, Christine Downey, Ryan T. Demmer, Pamela L. Lutsey, Souvik Sen: Nothing to disclose Figure 1 - belongs to Conclusions